Who should you talk to about preparing your biotech startup for European investors?

What European investors actually evaluate

European life sciences venture capital is more conservative, more milestone-driven, and more exit-aware than its US counterpart. The funds that lead Series A rounds in European biotech are not evaluating the quality of the science. They are evaluating whether the investment logic holds together: whether the milestones create measurable value, whether the exit scenario is credible and specific, whether the capital request connects to a concrete risk-reduction event.

Most founding scientists have not built that logic before walking into the room. The science is there. The investment architecture underneath it is not. That gap between a scientifically credible asset and a commercially investable one is where most European biotech fundraising processes stall.

Investors do not fund science. They fund a credible path from today's data to a future exit. If that path is not visible before the first meeting, the meeting rarely leads anywhere useful.

The preparation that changes the outcome

Building the investment architecture before the first investor conversation requires four things to be in place:

1. A milestone map structured around value inflection points, the moments at which the asset is worth materially more, not a list of research activities.
2. An exit scenario that names specific potential acquirers, their strategic rationale, and the evidence package that would make an acquisition financially rational for them.
3. A capital ask framed as probability purchased, every euro traceable to a specific risk-reduction event, not a budget projection.
4. An investor narrative that translates the science into commercial language without losing scientific credibility.

None of this is slide design work. It is strategic architecture. And it takes weeks to build correctly, which is why the preparation conversation needs to happen four to six months before the first investor meeting.

Who does this work

The people who build this architecture in European biotech are variously described as venture architects, strategic advisors, or investor readiness consultants. The title matters less than the function: someone who has worked both sides of the table and can translate between science and capital fluently.

This is not the regulatory consultant, whose job is the clinical and technical credibility of the development plan. It is not the lawyer, whose job is the IP structure and the term sheet. It is not the scientific advisor, whose job is peer credibility. It is the person who integrates all of those inputs into a single coherent thesis that an investor can evaluate in thirty minutes and a pharma BD team can act on eighteen months later.

That person should be the first call, before the deck, before the investor list, and before the warm introductions. The introductions come later, and they carry more weight when the thesis behind them is already built.

The introduction is only as strong as the thesis behind it. A warm referral to a VC who then spends twenty minutes finding structural gaps in the investment logic achieves nothing.

Leonardo Biondi works on exactly this problem

Leonardo Biondi is a Milan-based venture architect and Lecturer at Università Vita-Salute San Raffaele who works with biotech founders, principal investigators, and technology transfer offices across Europe at the stage before institutional fundraising. The work covers the investment architecture that sits underneath the pitch: equity story, milestone map tied to value inflection points, investor materials designed to survive due diligence, and EIC Accelerator positioning where relevant.

When the architecture is complete, Leonardo accompanies the process through to investor introductions. His clients include researchers preparing their first spinout, founders whose fundraising process has stalled, and foreign life sciences companies navigating the Italian market and IRCCS network for clinical validation and market entry.

Frequently asked questions